full list rate price target
earn chang report pleas see
tabl page
follow recent closur acquisit allergan result
fda approv eli lilli retevmo selpercatinib updat
model
ew close allergan acquisit may formal
updat integr model reflect partial recognit allergan sale
sales/expens base close date expect formal
guidanc call ep vs
prior stand-alon estim
ow follow print updat model reflect modestli
higher opex rel prior expect near term current
plan studi remain on-track and/or schedul start despit impact covid-
note note patient ftd phase studi
miss dose given site closur shelter-in-plac order interim
may help level-set expect readout expect net impact
chang bring ep
ow approv retevmo selpercatinib ret non-smal cell lung
cancer thyroid cancer formal roll model captur use
indic model peak sale high-profil readout tirzepatid
remain on-track near-term updat baracitinib
neutral antibodi potenti upsid catalyst given rel low street
expect program base formal inclus retevmo recent
trend across commerci portfolio rais ep
estim
updat follow releas file updat
follow model reflect actual ew ow gilead uw
merck ow ew ep estim unchang
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
summari rate price target earn chang report chang shown bold
barclay research share price target price shown primari list currenc ep estim shown report currenc
current fiscal year estim barclay research fiscal year estim barclay research
chang model
mn except per share datanewpriornewpriornewpriortot sales- gross total oper interest net- pre-tax tax expens benefit gaap net gaap ep share except per share datanewpriornewpriornewpriortot gross total oper interest oi pre-tax incom net incom common adjust ep share outstand barclay biopharmaceut
mn except per share datanewpriornewpriornewpriortot gross total interest oi incom net incom adj ep s/o barclay biopharmaceut
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
compel imbruvica venclexta commerci
perform expect humira biosimilar entrant
remain overhang allergan acquisiton
bolster durabl revenu base
still expect humira eros outpac growth
asset
commerci out-performance across skyrizi
rinvoq launch de-risk pipelin data ad
addit driver time-frame
offset humira eros
disappoint launch trajectori across rinvoq
skyrizi coupl neg shift humira eros
expect biosimilar
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight construct share
ahead like posit biomark readout
outsid share offer favor risk-reward
proof concept/biomark data year
posit could begin accret valu
posit neurocognit data phase ftd
studi line-of-sight toward acceler
approv file would upsid
right drive po higher latter rapidli
transform compani commercial-stag
failur demonstr biomark improv
ftd provid potenti read-through broader
immuno-neurolog platform/approach
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight durabl growth outlook
diabet favor trend improv
option oncolog margin expans
next decad low loe risk altogeth leav us
posit share compel setup
beyond alreadi higher-than-p multipl
alzheim prove viabl clinic trial win
tau a-beta competit verzenio data adjuv
breast cancer faster class growth
clinic trial setback tirzepatid key
unfavor chang regulatori polici
insulin poor payor access increas commerci
valuat methodolog risk
valuat methodolog price target share base dcf analysi assum wacc termin growth
long-term tax rate
risk may imped achiev barclay research valuat price upsid risk valuat hiccup
biosimilar humira launch commercial/clin setback competitor acceler clinic timelin key indic
greater synergi realiz allergan integr downsid risk includ clinic trial setback limit expans key product new
indic poor payor access face biosimilar brand competitor failur realiz synergi allergan transact
valuat methodolog pt reflect sum-of-the-part sotp analysi compris valuat contribut
po po assign valu platform net cash reflect
pro forma cash posit analysi reflect tax rate discount rate
risk may imped achiev barclay research valuat price downsid risk rate price target
includ pipelin clinic trial failur emerg advers safeti event lead pipelin product delay clinic trial timelin chang
partnership emerg new therapi ad alter scientif clinic commerci relev
product addit remain risk price assumpt ftd ad potenti pushback patient physician payor
valuat methodolog price target base blend dcf analysi wacc npv sum-of-the-
part npv sotp analysi reflect contribut lilli key commerci franchis endocrinolog oncolog
immunolog neurosci probabl adjust pipelin estim across key program selparactinib
tirzepatid alzheim effort net cash appli tax rate discount rate
risk may imped achiev barclay research valuat price risk valuat includ clinic trial
setback key pipelin program chang regulatori polici insulin payor access increas commerci competit
carter gould herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
